US 12,751,996 B2 · Application of TFF2 protein and IFN-κ protein combination in treatment of a novel coronavirus infection

Abstract

A TFF2 protein and an IFN-κ protein are combined to treat a novel coronavirus infection. A product comprises: (a) an IFN-κ protein; (b) a TFF2 protein; and (c) an optional pharmaceutically acceptable carrier. Provided are an application of a combination of IFN-κ protein and TFF2 protein in the preparation of a product for the treatment of a novel coronavirus infection and related diseases, and a method for using the product to treat a novel coronavirus infection and related diseases. The foregoing combination, application, and method have excellent therapeutic effects on novel coronavirus infections, and have application prospects and social benefits.

Claims8

Dependent claims

A method for treating novel coronavirus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a product comprising

(a) a TFF2 protein, wherein said TFF2 protein is selected from:
a polypeptide of the sequence set forth in SEQ ID NO:
1 or 2 or a polypeptide encoded by the nucleic acid molecule set forth in any of SEQ ID NOs:
3-6;
(b) an IFN-κ protein, wherein said IFN-κ protein is selected from:
a protein of the sequence set forth in SEQ ID NO:
7 or 8 or a polypeptide encoded by the nucleic acid molecule set forth in any of SEQ ID NOs:
9 to 12;
and
(c) optionally, a pharmaceutically acceptable carrier.

7 more elements

Dependencies are inferred from the claim text.

Application of TFF2 protein and IFN-κ protein combination in treatment of a novel coronavirus infection

Life of this patent

Application of TFF2 protein and IFN-κ protein combination in treatment of a novel coronavirus infection

Life of this patent

Abstract

Claims8